0460.HK
0460.HK
BMG8162K1137
SIHUAN PHARM
Loading chart...

Company Profile

Sihuan Pharmaceutical Holdings Group Ltd., an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical and medical aesthetic products in the People's Republic of China, the United States, and internationally. It operates in three segments: Medical Aesthetic Products, Innovative Medicine and Other Medicine, and Generic Medicine. The company offers filling, shaping, supporting, supplementing, optoelectronic devices, body sculpturing, skin care, and other services, as well as non- or minimally invasive comprehensive medical aesthetics solutions. It also provides drugs for cardio-cerebral vascular, digestive system, anti-infective, metabolism, respiratory, neurology, oncology, diabetes, and other indications, as well as modern Chinese medicine and industrial hemp products. In addition, the company offers general hospital services. Sihuan Pharmaceutical Holdings Group Ltd. was founded in 2001 and is based in Wan Chai, Hong Kong.

Related stocks

0570.HK
0570.HK • Hong Kong SAR China
TRAD CHI MED
1.27 HKD
815M USD 1Y -47.1%
2005.HK
2005.HK • Hong Kong SAR China
SSY GROUP
2.67 HKD
975.57M USD 1Y -10.6%
3613.HK
3613.HK • Hong Kong SAR China
TONGRENTANGCM
5.57 HKD
594.18M USD 1Y -37.8%
0512.HK
0512.HK • Hong Kong SAR China
GRAND PHARMA
4.74 HKD
2.12B USD 1Y -43.5%
2186.HK
2186.HK • China
LUYE PHARMA
1.73 HKD
880.63M USD 1Y -49.7%
4887.T
4887.T • Japan
SAWAI GROUP HOLDINGS CO LTD
1,629.5 JPY
1.19B USD 1Y -18.6%
MOREPENLAB.NS
MOREPENLAB.NS • India
MOREPEN LAB. LTD
129.55 INR
733.49M USD 1Y +170.4%
2877.HK
2877.HK • China
SHINEWAY PHARM
7.43 HKD
714.76M USD 1Y -12.9%

Key Metrics & Overview

Detailed metrics & financial data of the company

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High
5Y Volatility
53.1% p.a.
Max Drawdown (5Y)
-73.8%
Sharpe Ratio (5Y)
-0.30
Beta Factor
0.80
Size Class
Mid Cap
Notes & Warnings
Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
🔴 Low analyst coverage – higher uncertainty in growth estimates & projections
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (53.1% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -86.8% in the extended horizon.
ende